Advertisement

Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer

  • David S. Binns
  • Andrea Pirzkall
  • Wei Yu
  • Jason Callahan
  • Linda Mileshkin
  • Peter Conti
  • Andrew M. Scott
  • David Macfarlane
  • Bernard M. Fine
  • Rodney J. Hicks
  • OSI3926g Study Team
Original Article

Abstract

Purpose

The Response Evaluation Criteria in Solid Tumors (RECIST) are widely used but have recognized limitations. Molecular imaging assessments, including changes in 18F-deoxyglucose (FDG) or 18F-deoxythymidine (FLT) uptake by positron emission tomography (PET), may provide earlier, more robust evaluation of treatment efficacy.

Methods

A prospective trial evaluated on-treatment changes in FDG and FLT PET imaging among patients with relapsed or recurrent non-small cell lung cancer treated with erlotinib to assess the relationship between PET-evaluated response and clinical outcomes. We describe an audit of compliance with the study imaging charter, to establish the feasibility of achieving methodological consistency in a multicentre setting.

Results

Patients underwent PET scans at baseline and approximately day 14 and day 56 of treatment (n = 73, 66 and 51 studies, and n = 73, 63 and 50 studies for FDG PET and FLT PET, respectively). Blood glucose levels were within the target range for all FDG PET scans. Charter-specified uptake times were achieved in 86% (63/73) and 89% (65/73) of baseline FDG and FLT scans, respectively. On-treatment scans were less consistent: 72% (84/117) and 68% (77/113), respectively, achieved the target of ±5 min of baseline uptake time. However, 96% (112/117) and 94% (106/113) of FDG and FLT PET studies, respectively, were within ±15 min. Bland-Altman analysis of intra-individual hepatic average standardized uptake value (SUVave), to assess reproducibility, showed only a small difference in physiological uptake (−0.006 ± 0.224 in 118 follow-up FDG scans and 0.09 ± 0.81 in 111 follow-up FLT scans).

Conclusion

It is possible to achieve high reproducibility of scan acquisition methodology, provided that strict imaging compliance guidelines are mandated in the study protocol.

Keywords

Compliance PET acquisition protocols Erlotinib therapy Non-small cell lung cancer 

Notes

Acknowledgements

We would like to thank all the patients who participated in the study, and the clinical site teams: (in Australia) Peter MacCallum Cancer Centre, East Melbourne, Victoria; Austin Hospital, Heidelberg, Victoria; Royal Brisbane Women’s Hospital, Herston, Queensland; Prince Charles Hospital, Brisbane, Queensland; (in the USA) USC Medical Center Kenneth Norris Cancer Center, Los Angeles, CA; Pacific Cancer Medical Center, Inc, Anaheim, CA; St. Joseph Hospital, Regional Cancer Center, Orange, CA; and the Wilshire Oncology Medical Group, Inc., Corona, CA. We would like to acknowledge the site investigators Timothy Byun, Veena Charu, Barbara Gitlitz, Jeffrey Goh, Frank Howard, Brett Hughes, Samuel Kipper, Kai Lee, Paul Mitchell, and Hui Trung.

This work was supported financially by Genentech, Inc., South San Francisco, CA, USA. Drs. Pirzkall, Yu and Fine are employees at Genentech, Inc., and own stock with F. Hoffmann-La Roche, Ltd.

Genentech, Inc. provided assistance with preparation of the manuscript.

References

  1. 1.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.PubMedCrossRefGoogle Scholar
  2. 2.
    Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S–50.PubMedCrossRefGoogle Scholar
  3. 3.
    Tuma R. Sometimes size doesn’t matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst 2006;98:1272–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004;5:531–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773–82.PubMedCrossRefGoogle Scholar
  6. 6.
    Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791–8.PubMedGoogle Scholar
  7. 7.
    de Langen AJ, Klabbers B, Lubberink M, Boellaard R, Spreeuwenberg MD, Slotman BJ, et al. Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging 2009;36:389–95.PubMedCrossRefGoogle Scholar
  8. 8.
    Shields AF, Lawhorn-Crews JM, Briston DA, Zalzala S, Gadgeel S, Douglas KA, et al. Analysis and reproducibility of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4463–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Nahmias C, Wahl LM. Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. J Nucl Med 2008;49:1804–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Weber WA, Ziegler SI, Thödtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:1771–7.PubMedGoogle Scholar
  11. 11.
    Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995;196:167–73.PubMedGoogle Scholar
  12. 12.
    Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47:1059–66.PubMedGoogle Scholar
  13. 13.
    Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181–200.PubMedCrossRefGoogle Scholar
  14. 14.
    Erlotinib (Tarceva®) (package insert). South San Francisco: Genentech, Inc., 2007.Google Scholar
  15. 15.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32.PubMedCrossRefGoogle Scholar
  16. 16.
    Calvert H, Twelves C, Ranson M, Anthoney A, Plummer R, Fettner S, et al. The effect of erlotinib on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients: preliminary results. J Clin Oncol 2005;23 (June 1 Supplement):3076.Google Scholar
  17. 17.
    Velasquez LM, Boellaard R, Kollia G, Hayes W, Hoekstra OS, Lammertsma AA, et al. Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med 2009;50:1646–54.PubMedCrossRefGoogle Scholar
  18. 18.
    Beaulieu S, Kinahan P, Tseng J, Dunnwald LK, Schubert EK, Pham P, et al. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med 2003;44:1044–50.PubMedGoogle Scholar
  19. 19.
    Paquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med 2004;45:784–8.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • David S. Binns
    • 1
  • Andrea Pirzkall
    • 2
  • Wei Yu
    • 2
  • Jason Callahan
    • 1
  • Linda Mileshkin
    • 1
  • Peter Conti
    • 3
  • Andrew M. Scott
    • 4
  • David Macfarlane
    • 5
  • Bernard M. Fine
    • 2
  • Rodney J. Hicks
    • 6
    • 1
  • OSI3926g Study Team
  1. 1.The Peter MacCallum Cancer CentreMelbourneAustralia
  2. 2.Genentech, Inc.South San FranciscoUSA
  3. 3.University of Southern California Kenneth Norris Medical CenterLos AngelesUSA
  4. 4.Centre for PET, and Ludwig Institute for Cancer ResearchThe University of Melbourne and The Austin HospitalVictoriaAustralia
  5. 5.Queensland PET Service, Royal Brisbane and Women’s HospitalBrisbaneAustralia
  6. 6.Departments of Medicine and RadiologyThe University of Melbourne and The Peter MacCallum Cancer CentreEast MelbourneAustralia

Personalised recommendations